<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81851">
  <stage>Registered</stage>
  <submitdate>13/02/2007</submitdate>
  <approvaldate>19/02/2007</approvaldate>
  <actrnumber>ACTRN12607000134426</actrnumber>
  <trial_identification>
    <studytitle>N-acetylcysteine in Unipolar depression</studytitle>
    <scientifictitle>The Efficacy of N-acetylcysteine as an Adjunctive Treatment to improving depression in patients with Unipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial</scientifictitle>
    <utrn />
    <trialacronym>N-acetylcysteine</trialacronym>
    <secondaryid>NAC and UD</secondaryid>
    <secondaryid>NAC and UD</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Unipolar depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>N-acetylcysteine will be administered 2mg/day in two 500mg capsules to be taken twice daily for a duration of 8 weeks. Patients will be randomly assigned to N-acetylcysteine.</interventions>
    <comparator>Placebo will be administered 2mg/day in two 500mg capsules to be taken twice daily for a duration of 8 weeks. Patients will be randomly assigned to placebo group.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Montgomery Asberg depression Rating Scale (MADRS)</outcome>
      <timepoint>The scale will be administered at weeks 2, 4, 6  and 8 post-baseline intervals</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary outcomes include Clinical Global Impression - Improvement (CGI-I) and Severity (CGI-S), Global Assessment of Functioning Scale (GAF), Social and Occupational Functioning Assessment Scale (SOFAS), SLICE LIFE/LIFE RIFT, Quality of life Enjoyment &amp; Satisfaction Questionnaire (Q-Les-Q).</outcome>
      <timepoint>These scales will be administered at weeks 2, 4, 6, and 8 post-baseline intervals.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have capacity to consent, meet Diagnostic and Statistical Manual for Mental Disorders, Fourth edition, revision (DSM-IV-TR) criteria for major depressive disorder, have single episode or recurrent, achieve score of 18 or over on the MADRS at the time of trial entry, patients on antidepressant therapy need to have been on the same treatment for one month prior to randomisation, and if female of child bearing age and sexually active need to utilise effective contraception.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The exclusion criteria include individuals with concurrent diagnosis of bipolar I or II disorder, bipolar disorder not otherwise specified, electroconvulsive therapy for current depressive episode, concurrent primary diagnosis of a personality disorder, known or suspected clinically unstable systemic medical disorder, elderly subjects with respiratory insufficiency, recent gastrointestinal ulcers, pregnancy or breastfeeding, current use of greater than 500mg of NAC/day, 200mg of selenium or 500 IU of vitamin E/day, and history of anaphylactic reaction to NAC or any component of the preparation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment were randomly assigned into pack numbers by an individual independent of participant recruitment. Trial clinicians recruited participants and allocated them sequential pack numbers thereby adhering to double blind procedures.</concealment>
    <sequence>Treatments were allocated into pack numbers by a simple coin tossing method. Participants were then recruited and allocated sequential pack numbers.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Neither investigators nor patients are aware of which treatment aim the patients have been allocated. The blindness will be remained until the completion of the study.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/05/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Mental Health Research Institute</primarysponsorname>
    <primarysponsoraddress>Oak Street, Parkville</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Stanley Medical Research Institute</fundingname>
      <fundingaddress>8401 Connecticut Ave, Suite 200
Chevy Chase, MD 20815</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a novel study that investigates the benefits of NAC treatment in unipolar depression. Based on previous literature that reported deficits of this antioxidant in the brains of people with schizophrenia and bipolar disorder, the study postulates the deficits in unipolar depression patients. This trial involves adjunctive treatment where patients are received either NAC or placebo on top of their usual medication for a duration of 8 weeks.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress>Geelong </ethicaddress>
      <ethicapprovaldate>12/06/2007</ethicapprovaldate>
      <hrec>07/24</hrec>
      <ethicsubmitdate>29/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname> Royal North Shore Hospital,</ethicname>
      <ethicaddress>Sydney</ethicaddress>
      <ethicapprovaldate>18/09/2007</ethicapprovaldate>
      <hrec>0708-147M</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Health Care Group</ethicname>
      <ethicaddress>P O Box 126, Bendigo, 3552</ethicaddress>
      <ethicapprovaldate>23/11/2007</ethicapprovaldate>
      <hrec>9/2007</hrec>
      <ethicsubmitdate>17/07/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mental Health Research Institute</ethicname>
      <ethicaddress>Locked Bag 11, Parkville 3052</ethicaddress>
      <ethicapprovaldate>13/11/2007</ethicapprovaldate>
      <hrec>07/24_T1</hrec>
      <ethicsubmitdate>7/08/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Michael Berk</name>
      <address>Mental Health, Swanston Centre
PO Box 281 Geelong, VIC 3220</address>
      <phone>03 5226 7450</phone>
      <fax>03 5226 7436</fax>
      <email>mikebe@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Michael Berk</name>
      <address>Mental Health, Swanston Centre
PO Box 281 Geelong, VIC, 3220</address>
      <phone>03 5226 7450</phone>
      <fax>03 5226 7436</fax>
      <email>mikebe@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kristy Lu</name>
      <address>Mental Health, Swanston Centre PO Box 281 Geelong, VIC 3220</address>
      <phone>0352267428</phone>
      <fax />
      <email>kristylu@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>